US Patent

US12390439 — Oral liquid formulation of methocarbamol

Method of Use · Assigned to Liqmeds Worldwide Ltd · Expires 2044-10-09 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an oral liquid formulation of methocarbamol, specifically a suspension, and a process for preparing it for treating acute musculoskeletal pain.

USPTO Abstract

Disclosed herein is an oral liquid formulation of methocarbamol, which may be in the form of suspension. Also disclosed herein is a process for the preparing the oral liquid formulation of methocarbamol, and the use of the oral liquid formulation for the treatment of acute musculoskeletal pain.

Drugs covered by this patent

Robaxin (METHOCARBAMOL) · Hikma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4253`	—	Robaxin

Patent Metadata

Patent number: US12390439
Jurisdiction: US
Classification: Method of Use
Expires: 2044-10-09
Drug substance claim: No
Drug product claim: Yes
Assignee: Liqmeds Worldwide Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.